Intranasal immunization with W₈₀5EC adjuvanted recombinant RSV rF-ptn enhances clearance of respiratory syncytial virus in a mouse model

References

• Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009; 360:588 - 98; http://dx.doi.org/10.1056/NEJMoa0804877; PMID: 19196675
   PubMed Web of Science ®Google Scholar
• Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O’Brien KL, Roca A, Wright PF, Bruce N, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010; 375:1545 - 55; http://dx.doi.org/10.1016/S0140-6736(10)60206-1; PMID: 20399493
   PubMed Web of Science ®Google Scholar
• Sikkel MB, Quint JK, Mallia P, Wedzicha JA, Johnston SL. Respiratory syncytial virus persistence in chronic obstructive pulmonary disease. Pediatr Infect Dis J 2008; 27:Suppl S63 - 70; http://dx.doi.org/10.1097/INF.0b013e3181684d67; PMID: 18820581
   PubMedGoogle Scholar
• Wu P, Dupont WD, Griffin MR, Carroll KN, Mitchel EF, Gebretsadik T, Hartert TV. Evidence of a causal role of winter virus infection during infancy in early childhood asthma. Am J Respir Crit Care Med 2008; 178:1123 - 9; http://dx.doi.org/10.1164/rccm.200804-579OC; PMID: 18776151
   PubMed Web of Science ®Google Scholar
• Falsey AR. Respiratory syncytial virus infection in adults. Semin Respir Crit Care Med 2007; 28:171 - 81; http://dx.doi.org/10.1055/s-2007-976489; PMID: 17458771
   PubMed Web of Science ®Google Scholar
• De Serres G, Lampron N, La Forge J, Rouleau I, Bourbeau J, Weiss K, Barret B, Boivin G. Importance of viral and bacterial infections in chronic obstructive pulmonary disease exacerbations. J Clin Virol 2009; 46:129 - 33; http://dx.doi.org/10.1016/j.jcv.2009.07.010; PMID: 19665425
   PubMed Web of Science ®Google Scholar
• Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179 - 86; http://dx.doi.org/10.1001/jama.289.2.179; PMID: 12517228
   PubMed Web of Science ®Google Scholar
• Chanock RM, Parrott RH. Acute Respiratory Disease in Infancy and Childhood: Present Understanding and Prospects for Prevention. Pediatrics 1965; 36:21 - 39; PMID: 14313363
   PubMed Web of Science ®Google Scholar
• Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 1969; 89:435 - 48; PMID: 4305199
   PubMed Web of Science ®Google Scholar
• Schickli JH, Dubovsky F, Tang RS. Challenges in developing a pediatric RSV vaccine. Hum Vaccin 2009; 5:582 - 91; PMID: 19556888
   PubMed Web of Science ®Google Scholar
• Karron RA, Wright PF, Crowe JE Jr., Clements-Mann ML, Thompson J, Makhene M, Casey R, Murphy BR. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J Infect Dis 1997; 176:1428 - 36; http://dx.doi.org/10.1086/514138; PMID: 9395351
   PubMed Web of Science ®Google Scholar
• Wright PF, Karron RA, Belshe RB, Thompson J, Crowe JE Jr., Boyce TG, Halburnt LL, Reed GW, Whitehead SS, Anderson EL, et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 2000; 182:1331 - 42; http://dx.doi.org/10.1086/315859; PMID: 11010838
   PubMed Web of Science ®Google Scholar
• Cherukuri A, Stokes KL, Patton K, Kuo H, Sakamoto K, Lambert S, Stillman E, Moore ML, Lee S. An adjuvanted respiratory syncytial virus fusion protein induces protection in aged BALB/c mice. Immun Ageing 2012; 9:21; http://dx.doi.org/10.1186/1742-4933-9-21; PMID: 23031690
   PubMed Web of Science ®Google Scholar
• Kneyber MC, Kimpen JL. Advances in respiratory syncytial virus vaccine development. Curr Opin Investig Drugs 2004; 5:163 - 70; PMID: 15043390
   PubMedGoogle Scholar
• Singh SR, Dennis VA, Carter CL, Pillai SR, Moore EG. Respiratory syncytial virus recombinant F protein (residues 255-278) induces a helper T cell type 1 immune response in mice. Viral Immunol 2007; 20:261 - 75; http://dx.doi.org/10.1089/vim.2007.0008; PMID: 17603843
   PubMed Web of Science ®Google Scholar
• Feltes TF, Sondheimer HM, Tulloh RM, Harris BS, Jensen KM, Losonsky GA, Griffin MP, Motavizumab Cardiac Study Group. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. Pediatr Res 2011; 70:186 - 91; http://dx.doi.org/10.1203/PDR.0b013e318220a553; PMID: 21522037
   PubMed Web of Science ®Google Scholar
• Robinson KAOO, Odelola OA, Saldanha IJ, McKoy NA. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Cochrane Database Syst Rev 2012; 2:CD007743; PMID: 22336832
   PubMedGoogle Scholar
• Neuzil KM, Johnson JE, Tang YW, Prieels JP, Slaoui M, Gar N, Graham BS. Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine. Vaccine 1997; 15:525 - 32; http://dx.doi.org/10.1016/S0264-410X(97)00218-1; PMID: 9160520
   PubMed Web of Science ®Google Scholar
• Welliver RC, Tristram DA, Batt K, Sun M, Hogerman D, Hildreth S. Respiratory syncytial virus-specific cell-mediated immune responses after vaccination with a purified fusion protein subunit vaccine. J Infect Dis 1994; 170:425 - 8; http://dx.doi.org/10.1093/infdis/170.2.425; PMID: 8035030
   PubMed Web of Science ®Google Scholar
• Glenn GM, Smith G, Fries L, Raghunandan R, Lu H, Zhou B, Thomas DN, Hickman SP, Kpamegan E, Boddapati S, et al. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine 2013; 31:524 - 32; http://dx.doi.org/10.1016/j.vaccine.2012.11.009; PMID: 23153449
   PubMed Web of Science ®Google Scholar
• Langley JM, Sales V, McGeer A, Guasparini R, Predy G, Meekison W, Li M, Capellan J, Wang E. A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age. Vaccine 2009; 27:5913 - 9; http://dx.doi.org/10.1016/j.vaccine.2009.07.038; PMID: 19651171
   PubMed Web of Science ®Google Scholar
• Lindell DM, Morris SB, White MP, Kallal LE, Lundy PK, Hamouda T, Baker JR Jr., Lukacs NW. A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease. PLoS One 2011; 6:e21823; http://dx.doi.org/10.1371/journal.pone.0021823; PMID: 21789184
   PubMed Web of Science ®Google Scholar
• Renegar KB, Small PA Jr., Boykins LG, Wright PF. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol 2004; 173:1978 - 86; PMID: 15265932
   PubMed Web of Science ®Google Scholar
• Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986; 140:543 - 6; PMID: 3706232
   PubMedGoogle Scholar
• Luchsinger V, Piedra PA, Ruiz M, Zunino E, Martínez MA, Machado C, Fasce R, Ulloa MT, Fink MC, Lara P, et al. Role of neutralizing antibodies in adults with community-acquired pneumonia by respiratory syncytial virus. Clin Infect Dis 2012; 54:905 - 12; http://dx.doi.org/10.1093/cid/cir955; PMID: 22238168
   PubMed Web of Science ®Google Scholar
• Hurwitz JL. Respiratory syncytial virus vaccine development. Expert Rev Vaccines 2011; 10:1415 - 33; http://dx.doi.org/10.1586/erv.11.120; PMID: 21988307
   PubMed Web of Science ®Google Scholar
• Oien NL, Brideau RJ, Walsh EE, Wathen MW. Induction of local and systemic immunity against human respiratory syncytial virus using a chimeric FG glycoprotein and cholera toxin B subunit. Vaccine 1994; 12:731 - 5; http://dx.doi.org/10.1016/0264-410X(94)90224-0; PMID: 8091852
   PubMed Web of Science ®Google Scholar
• Makidon PE, Bielinska AU, Nigavekar SS, Janczak KW, Knowlton J, Scott AJ, Mank N, Cao Z, Rathinavelu S, Beer MR, et al. Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine. PLoS One 2008; 3:e2954; http://dx.doi.org/10.1371/journal.pone.0002954; PMID: 18698426
   PubMed Web of Science ®Google Scholar
• Makidon PE, Belyakov IM, Blanco LP, Janczak KW, Landers J, Bielinska AU, Groom JV 2nd, Baker JR Jr.. Nanoemulsion mucosal adjuvant uniquely activates cytokine production by nasal ciliated epithelium and induces dendritic cell trafficking. Eur J Immunol 2012; 42:2073 - 86; http://dx.doi.org/10.1002/eji.201142346; PMID: 22653620
   PubMed Web of Science ®Google Scholar
• Myc A, Kukowska-Latallo JF, Bielinska AU, Cao P, Myc PP, Janczak K, Sturm TR, Grabinski MS, Landers JJ, Young KS, et al. Development of immune response that protects mice from viral pneumonitis after a single intranasal immunization with influenza A virus and nanoemulsion. Vaccine 2003; 21:3801 - 14; http://dx.doi.org/10.1016/S0264-410X(03)00381-5; PMID: 12922114
   PubMed Web of Science ®Google Scholar
• Bettelli E, Oukka M, Kuchroo VKT. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007; 8:345 - 50; http://dx.doi.org/10.1038/ni0407-345; PMID: 17375096
   PubMed Web of Science ®Google Scholar
• Wang YH, Voo KS, Liu B, Chen CY, Uygungil B, Spoede W, Bernstein JA, Huston DP, Liu YJ. A novel subset of CD4(+) T(H)2 memory/effector cells that produce inflammatory IL-17 cytokine and promote the exacerbation of chronic allergic asthma. J Exp Med 2010; 207:2479 - 91; http://dx.doi.org/10.1084/jem.20101376; PMID: 20921287
   PubMed Web of Science ®Google Scholar
• Dominguez-Villar M, Hafler DA. Immunology. An innate role for IL-17. Science 2011; 332:47 - 8; http://dx.doi.org/10.1126/science.1205311; PMID: 21454778
   PubMed Web of Science ®Google Scholar
• Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, Cilley GE, Shen F, Eaton SM, Gaffen SL, Swain SL, et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007; 8:369 - 77; http://dx.doi.org/10.1038/ni1449; PMID: 17351619
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Lindell DM, Berlin AA, Morris SB, Shanley TP, Hershenson MB, Lukacs NW. IL-17-induced pulmonary pathogenesis during respiratory viral infection and exacerbation of allergic disease. Am J Pathol 2011; 179:248 - 58; http://dx.doi.org/10.1016/j.ajpath.2011.03.003; PMID: 21703407
   PubMed Web of Science ®Google Scholar
• Bielinska AU, Gerber M, Blanco LP, Makidon PE, Janczak KW, Beer M, Swanson B, Baker JR Jr.. Induction of Th17 cellular immunity with a novel nanoemulsion adjuvant. Crit Rev Immunol 2010; 30:189 - 99; http://dx.doi.org/10.1615/CritRevImmunol.v30.i2.60; PMID: 20370629
   PubMed Web of Science ®Google Scholar
• Das SC, Hatta M, Wilker PR, Myc A, Hamouda T, Neumann G, Baker JR Jr., Kawaoka Y. Nanoemulsion W805EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine. Vaccine 2012; 30:6871 - 7; http://dx.doi.org/10.1016/j.vaccine.2012.09.007; PMID: 22989689
   PubMed Web of Science ®Google Scholar
• Stanberry LR, Simon JK, Johnson C, Robinson PL, Morry J, Flack MR, Gracon S, Myc A, Hamouda T, Baker JR Jr.. Safety and immunogenicity of a novel nanoemulsion mucosal adjuvant W805EC combined with approved seasonal influenza antigens. Vaccine 2012; 30:307 - 16; http://dx.doi.org/10.1016/j.vaccine.2011.10.094; PMID: 22079079
   PubMed Web of Science ®Google Scholar
• Hamouda T, Sutcliffe JA, Ciotti S, Baker JR Jr.. Intranasal immunization of ferrets with commercial trivalent influenza vaccines formulated in a nanoemulsion-based adjuvant. Clin Vaccine Immunol 2011; 18:1167 - 75; http://dx.doi.org/10.1128/CVI.00035-11; PMID: 21543588
   PubMed Web of Science ®Google Scholar
• Makidon PE, Knowlton J, Groom JV 2nd, Blanco LP, LiPuma JJ, Bielinska AU, Baker JR Jr.. Induction of immune response to the 17 kDa OMPA Burkholderia cenocepacia polypeptide and protection against pulmonary infection in mice after nasal vaccination with an OMP nanoemulsion-based vaccine. Med Microbiol Immunol 2010; 199:81 - 92; http://dx.doi.org/10.1007/s00430-009-0137-2; PMID: 19967396
   PubMed Web of Science ®Google Scholar
• Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, Batalle JP, Diaz L, Trento A, Chang HY, Mitzner W, et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 2009; 15:34 - 41; http://dx.doi.org/10.1038/nm.1894; PMID: 19079256
   PubMed Web of Science ®Google Scholar
• Polack FP, Teng MN, Collins PL, Prince GA, Exner M, Regele H, Lirman DD, Rabold R, Hoffman SJ, Karp CL, et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med 2002; 196:859 - 65; http://dx.doi.org/10.1084/jem.20020781; PMID: 12235218
   PubMed Web of Science ®Google Scholar
• Hamouda T, Chepurnov A, Mank N, Knowlton J, Chepurnova T, Myc A, Sutcliffe J, Baker JR. Efficacy, immunogenicity and stability of a novel intranasal nanoemulsion-adjuvanted influenza vaccine in a murine model. Hum Vaccin 2010; 6:585 - 94; http://dx.doi.org/10.4161/hv.6.7.11818; PMID: 20421727
   PubMed Web of Science ®Google Scholar
• Tekkanat KK, Maassab H, Berlin AA, Lincoln PM, Evanoff HL, Kaplan MH, Lukacs NW. Role of interleukin-12 and stat-4 in the regulation of airway inflammation and hyperreactivity in respiratory syncytial virus infection. Am J Pathol 2001; 159:631 - 8; http://dx.doi.org/10.1016/S0002-9440(10)61734-8; PMID: 11485921
   PubMed Web of Science ®Google Scholar